|
|
Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea |
Seo Yeon Baik1, Hyunah Kim2, So Jung Yang1, Tong Min Kim1, Seung-Hwan Lee3, Jae Hyoung Cho3, Hyunyong Lee4, Hyeon Woo Yim5, Kun-Ho Yoon1,3, Hun-Sung Kim1,3() |
1. Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea 2. College of Pharmacy, Sookmyung Women’s University, Seoul 04310, Republic of Korea 3. Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea 4. Clinical Research Coordinating Center, Catholic Medical Center, The Catholic University of Korea, Seoul 06591, Republic of Korea 5. Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea |
|
|
Abstract Few long-term follow-up studies have compared the changes in renal function according to the type of statin used in Korea. We compared the long-term effects of statin intensity and type on the changes in the glomerular filtration rate (GFR). We extracted data of patients who took statin for the first time. We analyzed whether or not different statins affect the changes in GFR at 3 months after baseline and 4 years after. We included 3678 patients and analyzed the changes in GFR. The GFR decreased by 3.2%±0.4% on average 4 years after the first statin prescription, indicating statistically significant deterioration (from 83.5±0.4 mL/min/1.73 m2 to 79.9±0.4 mL/min/1.73 m2, P<0.001). When comparing the GFR among different statins, significant differences were observed between atorvastatin and fluvastatin (−5.3%±0.7% vs. 1.2%±2.2%, P<0.05) and between atorvastatin and simvastatin (−5.3%±0.7% vs. −0.7%±0.8%, P<0.05). In pitavastatin (odds ratio [OR]=0.64, 95% confidence interval [CI]=0.46–0.87, P<0.005) and simvastatin (OR=0.69, 95% CI=0.53–0.91, P<0.008), the GFR rate that decreased by<60 mL/min/1.73 m2 was significantly lower than that of atorvastatin. Regarding long-term statin intake, GFR changed with the type of statin. This work is the first in Korea to compare each statin in terms of changes in the GFR after the statin prescription.
|
Keywords
statin
glomerular filtration rate
HMG-CoA reductase inhibitor
chronic kidney disease
|
Corresponding Author(s):
Hun-Sung Kim
|
Just Accepted Date: 09 October 2018
Online First Date: 03 December 2018
Issue Date: 16 December 2019
|
|
1 |
SM Grundy. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319(1): 24–33
https://doi.org/10.1056/NEJM198807073190105
pmid: 3288867
|
2 |
MH Lee, HC Kim, SV Ahn, NW Hur, DP Choi, CG Park, I Suh. Prevalence of dyslipidemia among Korean adults: Korea national health and nutrition survey 1998–2005. Diabetes Metab J 2012; 36(1): 43–55
https://doi.org/10.4093/dmj.2012.36.1.43
pmid: 22363921
|
3 |
European Association for Cardiovascular Prevention & Rehabilitation, Z Reiner, AL Catapano, G De Backer, I Graham, MR Taskinen, O Wiklund, S Agewall, E Alegria, MJ Chapman, P Durrington, S Erdine, J Halcox, R Hobbs, J Kjekshus, PP Filardi, G Riccardi, RF Storey, D Wood; ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32(14): 1769–1818
https://doi.org/10.1093/eurheartj/ehr158
pmid: 21712404
|
4 |
JH Ahn, JH Yu, SH Ko, HS Kwon, DJ Kim, JH Kim, CS Kim, KH Song, JC Won, S Lim, SH Choi, K Han, BY Cha, NH Kim; Taskforce Team of Diabetes Fact Sheet of the Korean Diabetes Association. Prevalence and determinants of diabetic nephropathy in Korea: Korea national health and nutrition examination survey. Diabetes Metab J 2014; 38(2): 109–119
https://doi.org/10.4093/dmj.2014.38.2.109
pmid: 24851205
|
5 |
YH Kang, DW Jeong, SM Son. Prevalence of reduced kidney function by estimated glomerular filtration rate using an equation based on creatinine and cystatin C in metabolic syndrome and its components in Korean adults. Endocrinol Metab (Seoul) 2016; 31(3): 446–453
https://doi.org/10.3803/EnM.2016.31.3.446
pmid: 27491719
|
6 |
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis 2003; 41: I–IV, S1–91
|
7 |
R Agarwal. Effects of statins on renal function. Am J Cardiol 2006; 97(5): 748–755
https://doi.org/10.1016/j.amjcard.2005.09.110
pmid: 16490450
|
8 |
BS Moon, J Kim, JH Kim, YY Hyun, SE Park, HG Oh, CY Park, WY Lee, KW Oh, KB Lee, H Kim, SW Park, EJ Rhee. Eligibility for statin treatment in Korean subjects with reduced renal function: an observational study. Endocrinol Metab (Seoul) 2016; 31(3): 402–409
https://doi.org/10.3803/EnM.2016.31.3.402
pmid: 27586450
|
9 |
VG Athyros, DP Mikhailidis, AA Papageorgiou, AN Symeonidis, AN Pehlivanidis, VI Bouloukos, M Elisaf. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57(7): 728–734
https://doi.org/10.1136/jcp.2003.012989
pmid: 15220366
|
10 |
LF Fried, KY Forrest, D Ellis, Y Chang, N Silvers, TJ Orchard. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes. J Diabetes Complications 2001; 15(3): 113–119
https://doi.org/10.1016/S1056-8727(01)00140-4
pmid: 11358679
|
11 |
M Tonelli, C Isles, T Craven, A Tonkin, MA Pfeffer, J Shepherd, FM Sacks, C Furberg, SM Cobbe, J Simes, M West, C Packard, GC Curhan. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112(2): 171–178
https://doi.org/10.1161/CIRCULATIONAHA.104.517565
pmid: 15998677
|
12 |
TM Lee, MS Lin, CH Tsai, NC Chang. Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney Int 2005; 68(2): 779–787
https://doi.org/10.1111/j.1523-1755.2005.00457.x
pmid: 16014056
|
13 |
X Su, L Zhang, J Lv, J Wang, W Hou, X Xie, H Zhang. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis 2016; 67(6): 881–892
https://doi.org/10.1053/j.ajkd.2016.01.016
pmid: 26905361
|
14 |
J Kendrick, MG Shlipak, G Targher, T Cook, J Lindenfeld, M Chonchol. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis 2010; 55(1): 42–49
https://doi.org/10.1053/j.ajkd.2009.09.020
pmid: 19932541
|
15 |
T Acharya, J Huang, S Tringali, CR Frei, EM Mortensen, IA Mansi. Statin use and the risk of kidney disease with long-term follow-up (8.4-year study). Am J Cardiol 2016; 117(4): 647–655
https://doi.org/10.1016/j.amjcard.2015.11.031
pmid: 26742473
|
16 |
MM Garcia, CG Varela, PF Silva, PR Lima, PM Góes, MG Rodrigues, MdeL Silva, AM Ladeia, AC Guimarães, LC Correia. Endothelial effect of statin therapy at a high dose versus low dose associated with ezetimibe. Arq Bras Cardiol 2016; 106(4): 279–288
pmid: 27142792
|
17 |
AT Clarke, PC Johnson, GC Hall, I Ford, PR Mills. High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort. PLoS One 2016; 11(3): e0151587
https://doi.org/10.1371/journal.pone.0151587
pmid: 26983033
|
18 |
NJ Stone, JG Robinson, AH Lichtenstein, CN Bairey Merz, CB Blum, RH Eckel, AC Goldberg, D Gordon, D Levy, DM Lloyd-Jones, P McBride, JS Schwartz, ST Shero, SC Smith Jr, K Watson, PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Wilson 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2889–2934
https://doi.org/10.1016/j.jacc.2013.11.002
pmid: 24239923
|
19 |
HS Kim, H Lee, B Park, S Park, H Kim, SH Lee, JH Cho, KH Yoon, BY Cha, JH Kim, IY Choi. Comparative analysis of the efficacy of low- and moderate-intensity statins in Korea. Int J Clin Pharmacol Ther 2016; 54(11): 864–871
https://doi.org/10.5414/CP202332
pmid: 27487366
|
20 |
AS Levey, JP Bosch, JB Lewis, T Greene, N Rogers, D Roth; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130(6): 461–470
https://doi.org/10.7326/0003-4819-130-6-199903160-00002
pmid: 10075613
|
21 |
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–S266
pmid: 11904577
|
22 |
Centers for Disease Control and Prevention. Public health and aging: trends in aging—United States and worldwide. JAMA 2003; 289(11): 1371–1373
https://doi.org/10.1001/jama.289.11.1371
pmid: 12636453
|
23 |
HB Chae, SY Lee, NH Kim, KJ Han, TH Lee, CM Jang, KM Yoo, HJ Park, MK Lee, WS Jeon, SE Park, HS Moon, CY Park, WY Lee, KW Oh, SW Park, EJ Rhee. Age is the strongest effector for the relationship between estimated glomerular filtration rate and coronary artery calcification in apparently healthy Korean adults. Endocrinol Metab (Seoul) 2014; 29(3): 312–319
https://doi.org/10.3803/EnM.2014.29.3.312
pmid: 25309790
|
24 |
Q Fang, C Zou, P Zhong, F Lin, W Li, L Wang, Y Zhang, C Zheng, Y Wang, X Li, G Liang. EGFR mediates hyperlipidemia-induced renal injury via regulating inflammation and oxidative stress: the detrimental role and mechanism of EGFR activation. Oncotarget 2016; 7(17): 24361–24373
https://doi.org/10.18632/oncotarget.8222
pmid: 27014908
|
25 |
VM Campese, MK Nadim, M Epstein. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol 2005; 16(Suppl 1): S11–S17
https://doi.org/10.1681/ASN.2004110958
pmid: 15938026
|
26 |
A Verma, KM Ranganna, RS Reddy, M Verma, NF Gordon. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 2005; 96(9): 1290–1292
https://doi.org/10.1016/j.amjcard.2005.06.074
pmid: 16253600
|
27 |
G Yasuda, T Kuji, K Hasegawa, N Ogawa, G Shimura, D Ando, S Umemura. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Ren Fail 2004; 26(4): 411–418
https://doi.org/10.1081/JDI-120039826
pmid: 15462110
|
28 |
F Gueler, S Rong, JK Park, A Fiebeler, J Menne, M Elger, DN Mueller, F Hampich, R Dechend, U Kunter, FC Luft, H Haller. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol 2002; 13(9): 2288–2298
https://doi.org/10.1097/01.ASN.0000026609.45827.3D
pmid: 12191973
|
29 |
S Sharyo, N Yokota-Ikeda, M Mori, K Kumagai, K Uchida, K Ito, MJ Burne-Taney, H Rabb, M Ikeda. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int 2008; 74(5): 577–584
https://doi.org/10.1038/ki.2008.210
pmid: 18509318
|
30 |
C Quintavalle, D Fiore, F De Micco, G Visconti, A Focaccio, B Golia, B Ricciardelli, E Donnarumma, A Bianco, MA Zabatta, G Troncone, A Colombo, C Briguori, G Condorelli. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012; 126(25): 3008–3016
https://doi.org/10.1161/CIRCULATIONAHA.112.103317
pmid: 23147173
|
31 |
J Shepherd, JJ Kastelein, V Bittner, P Deedwania, A Breazna, S Dobson, DJ Wilson, A Zuckerman, NK; Treating to New Targets Investigators Wenger. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007; 2(6): 1131–1139
https://doi.org/10.2215/CJN.04371206
pmid: 17942759
|
32 |
H Nakamura, K Mizuno, Y Ohashi, T Yoshida, K Hirao, Y; MEGA Study Group. Uchida Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis 2009; 206(2): 512–517
https://doi.org/10.1016/j.atherosclerosis.2009.03.031
pmid: 19423108
|
33 |
H Kaneko, J Yajima, Y Oikawa, S Tanaka, D Fukamachi, S Suzuki, K Sagara, T Otsuka, S Matsuno, R Funada, H Kano, T Uejima, A Koike, K Nagashima, H Kirigaya, H Sawada, T Aizawa, T Yamashita. Effects of statin treatment in patients with coronary artery disease and chronic kidney disease. Heart Vessels 2014; 29(1): 21–28
https://doi.org/10.1007/s00380-013-0325-2
pmid: 23430269
|
34 |
S Shah, J Paparello, FR Danesh. Effects of statin therapy on the progression of chronic kidney disease. Adv Chronic Kidney Dis 2005; 12(2): 187–195
https://doi.org/10.1053/j.ackd.2005.01.007
pmid: 15822054
|
35 |
SL Seliger, NS Weiss, DL Gillen, B Kestenbaum, A Ball, DJ Sherrard, CO Stehman-Breen. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61(1): 297–304
https://doi.org/10.1046/j.1523-1755.2002.00109.x
pmid: 11786112
|
36 |
T Sakaeda, K Kadoyama, Y Okuno. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. PLoS One 2011; 6(12): e28124
https://doi.org/10.1371/journal.pone.0028124
pmid: 22205938
|
37 |
D de Zeeuw, DA Anzalone, VA Cain, MD Cressman, HJ Heerspink, BA Molitoris, JT Monyak, HH Parving, G Remuzzi, JR Sowers, DG Vidt. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol 2015; 3(3): 181–190
https://doi.org/10.1016/S2213-8587(14)70246-3
pmid: 25660356
|
38 |
MA Albert, RJ Glynn, FA Fonseca, AJ Lorenzatti, KC Ferdinand, JG MacFadyen, PM Ridker. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Am Heart J 2011; 162(1): 106–14.e2
https://doi.org/10.1016/j.ahj.2011.03.032
pmid: 21742096
|
39 |
JE Kwon, Y Kim, S Hyun, H Won, SY Shin, KJ Lee, SW Kim, TH Kim, CJ Kim. Cholesterol lowering effects of low-dose statins in Korean patients. J Lipid Atheroscler 2014; 3(1): 21–28 (in Korean)
https://doi.org/10.12997/jla.2014.3.1.21
|
40 |
M Kim, HK Kim, Y Ahn, H Park, MH Jeong, JG Cho, JC Park, YJ Kim, MC Cho, CJ Kim. Comparing high-intensity versus low-to moderate-intensity statin therapy in Korean patients with acute myocardial infarction. J Lipid Atheroscler 2014; 3(2): 97–104 (in Korean)
https://doi.org/10.12997/jla.2014.3.2.97
|
41 |
HS Kim, H Kim, YJ Jeong, TM Kim, SJ Yang, SJ Baik, SH Lee, JH Cho, IY Choi, KH Yoon. Development of clinical data mart of HMG-CoA r(HMG-CoA) Reductase inhibitor for varied clinical research. Endocrinol Metab (Seoul) 2017; 32(1): 90–98
https://doi.org/10.3803/EnM.2017.32.1.90
pmid: 28256114
|
42 |
KW Cho, SM Kim, CH An, YM Chae. Diffusion of electronic medical record based public hospital information systems. Healthc Inform Res 2015; 21(3): 175–183
https://doi.org/10.4258/hir.2015.21.3.175
pmid: 26279954
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|